KEDRION ACCELERATES GROWTH BUILT ON FOUNDATIONS OF TRANSFORMATION AND GLOBAL EXPANSION

• €1.65 billion revenues, up 4.5% compared to 2024, revenue built up from €1.57 billion in 2024 with growth and expansion focus 
• Adjusted EBITDA of €341.4 million 22.6% up on 2024, fourth consecutive year of double-digit EBITDA growth 
• Investment of €155 million (up 9% on 2024) supporting expansion and innovation
• 9.8% reduction in Net Financial Position, mainly driven by strong increase in operating cash flow, supported by higher EBITDA and disciplined working capital management

Castelvecchio Pascoli (Lucca), 20 April 2026: Kedrion, the international biopharmaceutical company focused on the production and distribution of plasma-derived therapies for rare, ultra-rare, and debilitating conditions completed another strong financial performance in 2025 as momentum builds on its transformative growth story.

Revenues reached €1.65 billion in 2025, up 4.5% in the year compounding consistent growth (from €1.57 billion in 2024) confirming Kedrion as the world’s 5^th largest company in plasma-derived products. 

Adjusted EBITDA of €341.4 million is 22.6% up on 2024 reflecting the fourth consecutive year of double-digit EBITDA growth. Kedrion also confirms a 9.8% reduction in Net Financial Position of €92.5m down to €853.3m following strong operating cash flow despite challenging macroeconomic headwinds.

Our revenues and EBIDTA reflect the strength of our operations and financial position, despite a challenging macroeconomic environment marked by US dollar depreciation. Revenue and adjusted EBITDA at constant currency generate a top line growth of 10% of and almost 30% of adjusted EBITDA growth compared to last year.

The United States continued to be Kedrion’s key growth driver and confirmed their position as the Company’s leading market due to a 61.2% share of revenue (56.7% in 2024). The launch of a new Immunoglobulin in late 2025 followed by the launch of another Immunoglobulin at the beginning of 2026, a therapy fully developed and manufactured within Kedrion, strengthened our portfolio in the US.

On the Company’s internationalization journey Kedrion has focused on key market expansion strengthening its presence in its key markets including Turkey, Mexico, Germany and the UK during 2025, enhancing capability to meet patient needs in therapeutic areas where plasma‑derived medicines play a vital role.

Our commitment to research and innovation was confirmed by Orphan Drug Designation for a Kedrion therapy for an ultra‑rare disease from both the Food and Drug Administration and the European Medicines Agency and three clinical trials progressed in parallel, confirming the value of our scientific work and our commitment to areas with limited therapeutic options. 

Kedrion’s manufacturing network delivered higher volumes, improved yields and greater efficiency, driven by capacity investments, higher throughput and increased operating leverage. In parallel, the continued optimization and expansion of plasma collection activities reinforced vertical integration, supply resilience and sustainable growth across the Company.

Ugo Di Francesco, Chief Executive Officer of Kedrion, said: “Our priority is building a globally leading biopharmaceutical company with a strong focus on rare and ultra-rare disease, capable of meeting an ever-increasing number of currently unmet therapeutic needs. Over the past four years, Kedrion has embarked on a growth pathway that represents much more than economic performance speaking to the strength of our organization, the solidity of our industrial roots, and our ability to innovate while staying true to our mission. We have integrated new capabilities, strengthened our supply chain, expanded our international footprint, and accelerated the development of therapies addressing unmet needs. Looking ahead, we will strengthen our operations and continue to expand our presence in markets where we can generate the greatest value for patients.”